temozolomide has been researched along with abt 869 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR | 1 |
1 other study(ies) available for temozolomide and abt 869
Article | Year |
---|---|
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Humans; Hypoxia; Indazoles; Mice; Mice, SCID; Phenylurea Compounds; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |